There are only three leadless cardiac pacemakers that have received a CE-mark to date, according to a recent guideline issued by the UK Medicines and Healthcare products Regulatory Agency on the clinical evaluation of such products. At the time of writing the March 2017 guideline, the MHRA said CE-marks had been awarded to St. Jude Medical Inc. ’s Nanostim and Medtronic PLC ’s Micra – both of which are intracardiac, entirely self-contained rate-responsive ventricular demand (VVIR) pacemakers. Also, CE-mark had been granted to EBR Systems Inc. ’ WICS, which effectively adds CRT (cardiac resynchronization therapy) capability to an existing transvenous Implanted pacemaker/implantable cardioverter defibrillator. Other leadless pacing systems are in development and it is thought that this modality may one day provide a wider range of therapies, including multisite endo- or epicardial pacing for CRT plus antitachycardia pacing in combination with non-transvenous ICDs.
To gain more insight on MHRA’s guideline on this topic, read Medtech Insight’s article here.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
